Calithera Biosciences Inc (CALA)

[djmurdock]

Yeah this sell off has been brutal. Way oversold.

[jimmy667]

Watching CALA as well. Cala Held up for a small gain in a broad-based market bloodbath. I use days like this as a stress test for stocks I watch. I look at all the ones that held up in the Universe of stocks I follow and drill down to the why.
Looks like it has bottomed out at 227 million market cap, almost unbelievable it fell this low as they are flush with $189 million in cash that they raised at the $9-10 level. $27 million received so far from Incyte with more to go.
Management expects to finish 2018 with $105-115 million left with readouts coming in 2018 late and 2019.Getting ready to start another trial and another one is being paid for by Incyte and another one near to finish enrollment.
My number one stock out of the 4-2-2018 'stress test' sell-off.
Good Luck!
Long CALA.

[Tdogwm]

Watching this one

[Cheetah SPEED]

Nice day here

My previous posts should be deleted. They are meaningless. I actually like this stock long

[Easymoneyman00]

Are you a total moron? Lol you better move along and get your shit together!

[Sikmarson]

Glutamine addiction in kidney cancer suppresses oxidative stress and can be exploited for real-time imaging

...Upon glutaminase inhibition with CB-839 or BPTES, the RCC cell lines SN12PM-6-1 (SN12) and 786-O exhibited decreased survival and pronounced apoptosis associated with a decreased GSH/GSSG ratio, augmented nuclear factor erythroid related factor 2 (NRF2), and increased 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG), a marker of DNA damage. SN12 tumor xenografts showed decreased growth when treated with CB-839...

Link: American Association for Cancer Research

[Sikmarson]

Experimental Calithera compound cripples key lung cancer mutations

...The researchers found that a mutated gene called KEAP1 teams up with another abnormal gene, KRAS, to cause lung cancer cells to grow aggressively. In so doing, they expel one type of glutamate and break down another to make energy. When the scientists tested CB-839 in mouse models of lung adenocarcinomas that had both mutations, the drug stopped the tumor growth....

Link: fiercebiotech

[eneels01]

Looking for an all time new high by EOY.

[Cheetah SPEED]

SCAM. SET BID .004

[Cheetah SPEED]

SELL THIS SCAM

$4 coming.....

AND SOON

[Cheetah SPEED]

This looks better. Just scared to chase it like you with gahc. Lol. I used to only trade pharma back in the day. I like this chart

[Copilotdog]

Check out AFMD

[Copilotdog]

Nope. Maybe today. But this will be $200 in two years if not BO before. Might see that within 6 months. Big boys have $50 calls for Sept

[Cheetah SPEED]

Like this one. Too late for entry co pilot dog?

[Sikmarson]

Wells Fargo & Co increase PT to 20$

source on twitter

[nlightn]

Bristol-Myers and Calithera expand clinical collaboration

May 15, 2017 6:56 AM ET

Bristol-Myers Squibb (NYSE:BMY) and Calithera Biosciences (NASDAQ:CALA) expand their cancer collaboration assessing Opdivo (nivolumab) and CB-839. They plan to evaluate the combination in non-small cell lung cancer (NSCLC) and melanoma. A clinical trial in clear cell renal cell carcinoma is already underway.

CB-839 is an orally administered inhibitor of an enzyme called glutaminase. It is designed to starve tumor cells of a protein called glutamine, a key nutrient. The rationale is that it may enhance the effects of checkpoint inhibitors and may reverse tumor resistance to checkpoint inhibitors by altering the immune-suppressive microenvironment and promoting an anti-tumor immune response. Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression.

[biotech2]

nice call. look at xxii, ovit and egbb

[stocktrademan]

CALA bullish 10.95









normal chart




log chart

[Sikmarson]

Next week presentation on Keystone symposia:

THURSDAY, MARCH 9

Ethan Emberley, Calithera Biosciences, USA
Short Talk: CB-839, a Selective Glutaminase Inhibitor, has Anti-Tumor Activity in Renal Cell Carcinoma and Synergizes with Everolimus and Cabozantinib

program

[jondoeuk]

What happened to the HK II inhibitor pipeline?

[biotech2]

I jumped into EGBB

[Sikmarson]

2 new cb-839 studies:

CB-839 + Azacitidine for Treatment of Myelodysplastic Syndrome (MDS)
cinical trials.gov

Study of CB-839 in Combination w/ Paclitaxel in Patients of African Ancestry and Non-African Ancestry With Advanced TNBC
clinical trials.gov

[biotech2]

nice read, should have bought a few weeks back. for a real flyer check out EGBB

[mjw007]

Yes

[trendmkr]

Calithera Biosciences Inc (NASDAQ:CALA): What You Need To Know https://marketexclusive.com/calithera-biosciences-inc-nasdaqcala-need-know/70715/?icd1

[ClayTrader]

* * $CALA Video Chart 01-30-17 * *

Link to Video - click here to watch the technical chart video

[G3TCRUNK3R]

I must be missing something. Sorry. How is this going to go up with a share offering at 4.65? It's going to come down hard.

[xfrozenx]

Anyone see this hitting 10?

[Mistr Tommy]

cala not stopping at all

[TheFinalCD]

Filled Sell 1100 CALA Limit 7.20 -- -- 10:43:11 01/30/17

Filled Sell 900 CALA Limit 7.20 -- -- 10:43:11 01/30/17

[TheFinalCD]

6.45!!

[Sikmarson]

Compositions and Methods for Inhibiting Arginase Activity
Publication Number:20160375044
Publication Date: 29.12.2016

link patenscope

COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
Pub. No.: WO/2016/210106
Publication Date: 29.12.2016

link patentscope

HETEROCYCLIC INHIBITORS OF GLUTAMINASE
Publication Number: 10201607685S
Publication Date: 29.11.2016

link patentscope

[ClayTrader]

* * $CALA Video Chart 12-21-16 * *

Link to Video - click here to watch the technical chart video

[TheFinalCD]

GOOO CALA

http://finance.yahoo.com/news/bristol-myers-squibb-calithera-biosciences-115900976.html

[PStockPickz]

heating back up

[PStockPickz]

this ones looking good for today

[Stockyang]

Almost the time to breakout

[DJ2NAZTY]

Got in at 2.96 holding 700 shares. Been reading Alot of people bashing this stock on other boards. I always say time to buy in when the Badgers fly in!

[Cokezero]

Dat spead

[Sikmarson]

New trial at ClinicalTrials.gov:

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Sponsor:
Case Comprehensive Cancer Center
link

[blindjohn]

Broke out!

[TheTanMan]

Let's break out Cala . Stop taking your time

[Warchest]

$3.32 up

[jondoeuk]

Calithera Biosciences Announces FDA Acceptance of Investigational New Drug Application for CB-1158, a Novel Arginase Inhibitor Targeting an Immune Metabolic Checkpoint

SOUTH SAN FRANCISCO, Calif., July 25, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for CB-1158 for the treatment of solid tumors. CB-1158 is a first-in-class, orally available small molecule inhibitor of the enzyme arginase.

"We are pleased to be advancing the first arginase inhibitor into clinical trials. Arginase is a novel target in metabolic immuno-oncology, and these studies will allow us to assess the safety, pharmacokinetics and pharmacodynamics of this exciting new agent," said Susan M. Molineaux, Ph.D., founder, Chief Executive Officer and President of Calithera Biosciences. "CB-1158 has demonstrated significant anti-tumor activity in preclinical models, and we look forward to reporting initial clinical results with this compound in 2017.”

Arginase exerts its immunosuppressive effect by depleting the amino acid arginine in the tumor microenvironment and prevents activation and proliferation of the immune system’s cytotoxic T-cells and natural killer (NK) cells. Inhibition of arginase activity reverses this immunosuppressive block and restores T-cell function. The Phase I clinical trial will enroll patients with advanced solid tumors treated with CB-1158 as a monotherapy, as well as in combination with an anti-PD1 antibody.

http://ir.calithera.com/phoenix.zhtml?c=253557&p=irol-newsArticle&ID=2187727

[Warchest]

$3.30 BREAK COMING

[The Market Maker]

Picked up a few shares just now

[Warchest]

chart looks ready ~ slappers takes her up !!

[crudeoil24]

Yup! > Form 4's out. nice gains.

[ClearlyStocks]

Issue is that keep buying shares for under $1, hence the dilution. I sold for profit few days ago

[Warchest]

Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating: Buy (Score: 3.00)
Consensus Price Target: $12.00 (289.61% upside)